# Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)

> **NCT07521670** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Centre, Singapore** · enrollment: 68 (estimated)

## Conditions studied

- Recurrent Adenoid Cystic Carcinoma
- Adenoid Cystic Carcinoma Metastatic
- Papillary Thyroid Carcinoma

## Interventions

- **DRUG:** Sacituzumab Tirumotecan

## Key facts

- **NCT ID:** NCT07521670
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07521670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07521670, "Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07521670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*